Literature DB >> 6484118

Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy.

D J Hosking, D Gilson.   

Abstract

The hypocalcaemic response to salmon calcitonin was separated into its renal and skeletal components during the treatment of 21 patients with severe hypercalcaemia complicating malignant disease. Inhibition of renal tubular calcium reabsorption by calcitonin may induce a rapid fall in serum calcium. The magnitude of this response depends in part upon the correction of volume depletion which is a common feature of hypercalcaemia from any cause. The adequacy of rehydration can be assessed from the relationship between serum calcium and the calcium excretion rate expressed in mumol/l glomerular filtrate (CaE). Not all patients show a good renal response to calcitonin and this may reflect secretions by the primary tumour of substances which inhibit the renal tubular actions of calcitonin. The response to rehydration may identify such patients and this has obvious practical implications for the choice of treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6484118

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  15 in total

Review 1.  Emergencies of calcium homeostasis.

Authors:  Jean-Jacques Body; Roger Bouillon
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

Review 2.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

3.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.

Authors:  S Fatemi; F R Singer; R K Rude
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 4.  Assessment of renal and skeletal components of hypercalcemia.

Authors:  D J Hosking
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

5.  Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.

Authors:  S H Ralston; A A Alzaid; M D Gardner; I T Boyle
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-14

6.  Renal handling of calcium and sodium in metastatic and non-metastatic malignancy.

Authors:  S R Heller; D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

7.  Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy.

Authors:  D J Hosking; M D Stone; J W Foote
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 8.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

9.  Quantitation of the renal effect of calcitonin in the hypercalcaemia of malignancy.

Authors:  D J Hosking; S R Heller
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 10.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.